The Importance of Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography/Computed Tomography, and Biopsy for Identifying and Delineating the Extent of Intraprostatic Radiorecurrent Prostate Cancer: A Secondary Analysis of the F-SHARP Clinical Trial
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2025.02.042 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von BhanuPrasad Venkatesulu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Loyola University Chicago, Loyola University Medical Center, Stritch School of Medicine, Cardinal Bernardin Cancer …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Neoplasm Recurrence, Local, Multiparametric Magnetic Resonance Imaging. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Up to 50% of clinical recurrences after curative-intent prostate cancer radiation are intraprostatic radiorecurrences (IPRRs). Salvage local therapy (SLT) is increasingly offered, particularly as focal SLT, to reduce toxicity due to prior radiation. Limited data exist on the relative value of magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT), and biopsy on SLT target delineation. We compared MRI, PET/CT, and biopsy in patients with IPRRs and the impact each modality has on identifying IPRRs and defining the extent of prostatic involvement. METHODS AND MATERIALS: We performed a secondary analysis of 62 patients enrolled in a phase 1/2 clinical trial of salvage high-dose-rate brachytherapy. The IPRR was delineated using each imaging modality and by defining the involved regions of the prostate on biopsy. The exact binomial distribution was used to estimate the sensitivity of MRI and PET/CT to detect the IPRR. Exact conditional logistic regression was used to compare the tumor identified by MRI and PET/CT with the areas of biopsy involvement (gold standard) and estimate the proportion of patients with prostatic involvement outside of the image-defined targets. RESULTS: The sensitivity for detecting the IPRR was 91.8% for MRI and 85.5% for PET/CT. Most patients had biopsy-proven cancer outside of the MRI-defined (70.5%) and PET/CT-defined (73.8%) target. Delineating the brachytherapy target using imaging only would have missed the full extent of recurrence in 63.9%. CONCLUSIONS: Although MRI and PET/CT are valuable, a thorough biopsy is a mandatory tool to avoid missing areas of imaging-occult prostatic involvement when delivering focal SLT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Loyola University Chicago, Loyola University Medical Center, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Maywood, Illinois; Department of Radiation Oncology, Universit…
- Department of Medicine, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois.
- Department of Radiation Oncology, Loyola University Chicago, Loyola University Medical Center, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Maywood, Illinois.
- Department of Urology, Loyola University Chicago, Loyola University Medical Center, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Maywood, Illinois.
- Department of Pathology, Loyola University Chicago, Loyola University Medical Center, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Maywood, Illinois.
- Department of Radiology and Medical Imaging, Loyola University Chicago, Loyola University Medical Center, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Maywood, Illinois.
Zitieren
APA
Venkatesulu, B., Adams, W., Joel, R., Ross, D., Yoo, R., Quick, C., Baldea, K. G., Barkan, G., Block, A., Bova, D., Farooq, A., Garant, A., Gupta, G., Shea, S. M., Showalter, T. N., Small, W., Welsh, J. S., Harkenrider, M. M., & Solanki, A. A. (2025). The Importance of Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography/Computed Tomography, and Biopsy for Identifying and Delineating the Extent of Intraprostatic Radiorecurrent Prostate Cancer: A Secondary Analysis of the F-SHARP Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.02.042
Vancouver
Venkatesulu B, Adams W, Joel R, Ross D, Yoo R, Quick C, et al. The Importance of Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography/Computed Tomography, and Biopsy for Identifying and Delineating the Extent of Intraprostatic Radiorecurrent Prostate Cancer: A Secondary Analysis of the F-SHARP Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.02.042
BibTeX
@article{Venkatesulu2025,
author = {Venkatesulu, BhanuPrasad and Adams, William and Joel, Rebecca and Ross, Dylan and Yoo, Ryan and Quick, Carly and Baldea, Kristin G and Barkan, Guliz and Block, Alec and Bova, Davide and Farooq, Ahmer and Garant, Aurelie and Gupta, Gopal and Shea, Steven M and Showalter, Timothy N and Small, William and Welsh, James S and Harkenrider, Matthew M and Solanki, Abhishek A},
title = {The Importance of Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography/Computed Tomography, and Biopsy for Identifying and Delineating the Extent of Intraprostatic Radiorecurrent Prostate Cancer: A Secondary Analysis of the F-SHARP Clinical Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2025.02.042}
}
EUVIMED